Incidence of Right Ventricular Dysfunction in an Echocardiographic Referral Cohort

Jonah D. Garry; Shi Huang; Jeffrey Annis; Suman Kundu; Anna Hemnes; Matthew Freiberg; Evan L. Brittain

doi:10.1101/2024.10.08.24315120

Abstract

Introduction Incidence rates (IRs) of RV dysfunction (RVD) are unknown. We examined the rates, risk factors, and heart failure (HF) hospitalization hazard associated with incident RVD in patients referred for Transthoracic Echocardiogram (TTE).

Methods In this retrospective cohort study, we extracted tricuspid regurgitant velocity (TRV) and tricuspid annular systolic plane excursion (TAPSE) from TTEs at Vanderbilt (2010-2023). We followed patients from their earliest TTE with normal RV function (TAPSE≥17mm) and a reported TRV. The primary outcome was new RVD (TAPSE<17mm), and the secondary outcome was HF hospitalization after second TTE. Poisson regression and multivariable cox models estimated IRs and hazard ratios, adjusted for demographics, comorbidities, and TTE measures.

Results Among 45,753 patients (63 years [IQR 50-72], 45% Male, 13% Black) meeting inclusion criteria, 13,735 (30.1%) underwent a follow up TTE and 4,198 (9.2%) developed RVD. The IR of RVD in the full cohort was 3.2/100 person/years (95%CI 3.1-3.3) and 8.2 (95%CI 8.0-8.5) in the repeat TTE cohort. IRs increased with rising RVSP. Risk factors for incident RVD were most prominently HF (HR 1.88; 95%CI 1.75–2.03), left-sided valvular disease (HR 1.68; 95%CI 1.53–1.85), and other cardiovascular comorbidities. Baseline RVSP >35 mmHg associated with TAPSE decline over time. Incident RVD increased hazard of HF hospitalization (HR 2.02; 95%CI 1.85-2.21). Hazard of HF hospitalization increased when TAPSE declined by ≥5mm.

Conclusions RVD incidence is substantial among patients referred for TTE. Clinical monitoring is warranted if RVSP >35mmHg. Cardiovascular comorbidities drive RVD in this population. Incident RVD associates with increased hazard of HF hospitalization.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Heart Lung and Blood Institute: T32 HL 087738 (Garry), R01 HL 163960 (Brittain), R01 HL 146588 (Brittain, Freiberg), R01 HL 155278 (Brittain); National Institute of Diabetes and Digestive and Kidney Diseases: R01 DK 124845 (Brittain); and US Food and Drug Administration R01 FD 007627 (Brittain).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board of Vanderbilt University Medical Center gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Conflicts of Interest: None
Funding: This work was supported by the National Heart Lung and Blood Institute: T32 HL 087738 (Garry), R01 HL 163960 (Brittain), R01 HL 146588 (Brittain, Freiberg), R01 HL 155278 (Brittain); National Institute of Diabetes and Digestive and Kidney Diseases: R01 DK 124845 (Brittain); and US Food and Drug Administration R01 FD 007627 (Brittain).